Venrock

Astronomer is a data engineering software company that builds a managed Apache Airflow platform. Founded in 2014 and based in Cincinnati, Astronomer offers Astro, a data orchestration platform powered by Apache Airflow that enables data teams to build, run, and observe data pipelines-as-code. The platform is designed to deploy, manage, and scale distributed Airflow workflows with features such as isolated resource allocation and controlled user access, supporting data engineers, data scientists, and data analysts in delivering trusted analytics. Astronomer's solutions help organizations increase data availability and visibility by making pipelines observable and governance-friendly across environments.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Expedition Therapeutics offers biopharmaceutical development services for translational research and global licensing. The company identifies and licenses novel therapeutic candidates, conducts preclinical and clinical validation, and manages regulatory pathways and commercialization partnerships, enabling pharmaceutical firms and investors to access promising assets from emerging markets, accelerate development timelines, and expand international pipelines.

Auditoria.AI, Inc. is a technology company based in Santa Clara, California, founded in 2019. It specializes in providing innovative financial solutions for enterprise accounting and audit, utilizing advanced artificial intelligence and machine learning technologies. The company focuses on enhancing compliance and automating finance back-office processes through its flagship product, which employs natural language processing and predictive analytics. By streamlining operations and reducing redundancy, Auditoria.AI aims to support finance teams in making informed, data-driven decisions and improving overall efficiency.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Exceeds is a technology company that specializes in enhancing the productivity and performance of engineering teams. It offers a platform that leverages AI and data insights to capture daily work activities and feedback, identify skill gaps, and provide targeted support. This enables engineers to work more efficiently and effectively, without the need for micromanagement.

GenLogs is a technology company specializing in freight intelligence. It operates a platform that uses AI and a nationwide sensor network to monitor and analyze logistics operations and supply chains. The platform identifies reliable truck carriers based on specific equipment and lane requirements, tracks shipments, trailers, and equipment, and provides insights to enhance operational efficiency, reduce fraud risks, and support informed decision-making.

Oumi is a technology company that develops an open-source AI platform. This platform assists businesses in building, evaluating, and deploying advanced AI models at scale. It offers features like intelligent document processing, automated data extraction, and customizable workflows, helping businesses across industries enhance efficiency, reduce manual effort, and make data-driven decisions. The company is founded and operated by a team of academics and developers committed to promoting transparency and collaboration in frontier AI.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Scope3 provides a supply chain emissions data platform that serves as the source of truth for corporate greenhouse gas information. The company models the core inputs and outputs of products and services across the supply chain, designs systems to reduce environmental impact, and produces monthly sustainability reports that update with fresh data. This enables organizations to factor emissions into business decisions, respond rapidly to changes, and receive recognition for investments in reducing their carbon footprint.

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms. Built by estate professionals and advisors, the platform allows advisors, planners, and estate attorneys to provide comprehensive and modern estate planning services to their clients. By streamlining the estate analysis process, Vanilla addresses inefficiencies in document preparation and improves both advisors' and clients' understanding of estate matters. The platform aims to simplify the complexities of estate management, thereby enabling advisors to strengthen client relationships, attract new business, and deliver ongoing value through effective estate planning solutions.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company dedicated to the identification, development, and commercialization of products aimed at addressing cardiovascular and pulmonary diseases with significant unmet medical needs. Headquartered in Morrisville, North Carolina, Tenax focuses on levosimendan, a pharmaceutical product designed to reduce morbidity and mortality in cardiac surgery patients at risk for low cardiac output syndrome. The company is also actively conducting a Phase 2 clinical trial to explore the efficacy of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction. Additionally, Tenax is involved in developing novel formulations of imatinib mesylate, a kinase inhibitor with the potential to serve as a disease-modifying therapy for pulmonary arterial hypertension. Founded in 1967, Tenax Therapeutics underscores its commitment to advancing treatments within these critical therapeutic areas.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Tembo develops a background engineering platform that automates routine tasks for software teams. Its always-on agents monitor systems, fix bugs automatically, and complete assigned tasks, enhancing pull request velocity and reducing manual workload.

CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Archetype AI is a group of designers and technologists they are pioneering revolutionary artificial intelligence and interaction technologies for the real world.

Mirador Therapeutics specializes in developing precision medicine technologies to tackle immune-mediated inflammatory and fibrotic diseases. The company's core offering is a proprietary data analytics engine that integrates comprehensive patient molecular profiles, pinpoints novel therapeutic targets, and facilitates the creation of targeted diagnostics. This enables researchers and healthcare providers to tailor treatments to individual patients' genetics, potentially enhancing outcomes for those with chronic conditions.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Applied Therapeutics is a biopharmaceutical company focused on developing transformative drugs targeting fatal and debilitating diseases with high unmet medical needs. Its pipeline includes novel product candidates such as AT-007 for rare metabolic diseases like galactosemia, AT-001 for diabetic cardiomyopathy, and AT-003 for diabetic retinopathy.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

Accompany Health provides comprehensive in-home primary care, including chronic illness management and treatment of new symptoms, and coordinates care across the full patient journey. The company offers at-home and virtual care, with round-the-clock support to address health needs any time, day or night. It focuses on cultivating long-term relationships with patients, ensuring consistent access to care and a stable point of contact year after year. Accompany Health serves individuals with complex needs, including low-income populations, helping them manage health journeys effectively and improve outcomes. By combining clinical delivery with technology-enabled care coordination, the company aims to reduce barriers such as waiting rooms and lines and to provide dignified care that supports patients throughout ongoing management of chronic conditions and new symptoms.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Founded in San Francisco in 2016, SmithRx specializes in designing and managing custom pharmacy benefit plans for companies. It leverages a modern technology platform to deliver flexibility, efficiency, and customer satisfaction, aligning incentives through data analytics.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Zero Networks Inc. is a network security software developer founded in 2019 and headquartered in Tel Aviv, Israel. The company specializes in automating the definition, enforcement, and adaptation of network access policies for users and machines within an organization. Its cloud-based technology customizes access controls by learning how users and devices communicate, thereby enhancing security without the need for agents or complex policy configurations. Additionally, Zero Networks incorporates a two-factor authentication mechanism that allows legitimate but unusual connections through a secure wall on mobile devices. This approach ensures robust protection against potential breaches while maintaining operational continuity, making it an effective solution for organizations seeking to strengthen their network security posture.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies to transform the treatment of inflammatory bowel disease (IBD).

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients. The company specializes in the development of antibody-drug conjugates (ADCs) targeting novel oncology targets. By utilizing innovative technology, MBrace Therapeutics creates anti-tumor monoclonal human recombinant antibodies that specifically target cancer cells. This approach allows for the precise delivery of toxic agents directly into the cancer cells, enabling healthcare professionals to more effectively treat various forms of cancer.

Scope3 provides a supply chain emissions data platform that serves as the source of truth for corporate greenhouse gas information. The company models the core inputs and outputs of products and services across the supply chain, designs systems to reduce environmental impact, and produces monthly sustainability reports that update with fresh data. This enables organizations to factor emissions into business decisions, respond rapidly to changes, and receive recognition for investments in reducing their carbon footprint.

Moment is a provider of fixed‑income infrastructure and liquidity solutions for institutional and fintech clients. The company offers an institutional‑grade platform and APIs that power fixed‑income investing, combining trading, research, portfolio optimization, reporting, risk and compliance in a single system with automation. Moment serves global fintechs, traditional brokerages, and registered investment advisors, delivering modern fixed‑income tools to make markets more equitable and accessible. By unifying core fixed‑income functions and offering liquidity capabilities, Moment supports institutions in managing, pricing, and executing fixed‑income strategies at scale, enabling faster decision‑making and greater efficiency across the investment process.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

SQLite Cloud is a cloud-based service that offers an easy-to-use and highly scalable platform for managing SQLite databases in the cloud. Our product provides a secure and reliable way to store, manage, and share SQLite databases without requiring any server setup or maintenance. With our service, customers can easily create new databases, import existing databases, and collaborate with others on their projects. Our product also offers various features such as automated backups, point-in-time recovery, and real-time replication, which ensures high availability and data durability. Our goal is to make database management as easy and hassle-free as possible for our customers.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Aledade is a health technology and services platform that partners with independent primary care physicians to form and operate Accountable Care Organizations in the United States. It provides data analytics, guided workflows, regulatory and contracting support, payer relationships, and local on-the-ground expertise to help practices transform operations, optimize care delivery, and align incentives around value-based care. The platform integrates care data across the continuum, offers practice management tools, and supports governance and policy guidance to enable autonomous physician groups—from small practices to multispecialty networks and community health centers—to improve patient outcomes while reducing overall costs. Headquartered in Bethesda, Maryland, the company was founded in 2014.

NeoPhotonics is a technology company specializing in the development, manufacture, and sale of optical components and subsystems used in high-speed digital communications networks. The company offers a comprehensive range of active and passive optical products tailored for various market segments, including fiber-to-the-home (FTTH), data communications, storage area networks, and both metro and long-haul networks. Its product lineup includes transceivers, integrated splitters, multiplexers, and advanced optical modules, all designed to support a wide array of data rates and applications. Notably, NeoPhotonics is recognized for its innovative silica Planar Lightwave Circuit (PLC) technology, which plays a crucial role in modern optical networks. Additionally, the company produces MEMS-based Variable Optical Attenuators and Dynamic Channel Equalizers, enhancing the performance and efficiency of communication systems.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

Vocera Communications, Inc. specializes in providing secure and integrated communication and workflow solutions tailored for mobile workers across various sectors, including healthcare, hospitality, retail, energy, and education. The company’s offerings enhance communication and operational efficiency by integrating with existing clinical systems, such as electronic health records and nurse call systems. Vocera's product suite includes the Vocera Communication and Workflow System, which connects various communication devices, including hands-free and voice-controlled options, and the Vocera Care Experience software, designed to improve patient care quality and streamline manual tasks. Additionally, Vocera operates the Experience Innovation Network, collaborating with healthcare organizations to develop innovative solutions that improve patient and care team experiences. The company, founded in 2000 and headquartered in San Jose, California, serves approximately 1,700 healthcare facilities globally, including hospitals and clinics, and distributes its products through direct sales, resellers, and distributors.

Airspeed is a developer of team-building software designed to enhance digital connections within modern companies. Its platform offers a suite of applications that provide engaging solutions for celebrating employee milestones, recognizing colleagues, and fostering connections among hybrid and remote teams. By serving as a system of record for company culture, Airspeed helps organizations cultivate a strong environment of engagement, recognition, and collaboration, ultimately improving employee retention and productivity.

Applied Therapeutics is a biopharmaceutical company focused on developing transformative drugs targeting fatal and debilitating diseases with high unmet medical needs. Its pipeline includes novel product candidates such as AT-007 for rare metabolic diseases like galactosemia, AT-001 for diabetic cardiomyopathy, and AT-003 for diabetic retinopathy.

Tembo develops a background engineering platform that automates routine tasks for software teams. Its always-on agents monitor systems, fix bugs automatically, and complete assigned tasks, enhancing pull request velocity and reducing manual workload.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Nightfall offers a cloud data protection platform and developer platform that uses machine learning to identify and classify sensitive business data across SaaS apps, APIs, and data infrastructure. It detects exposures, automates data hygiene, and enforces workflows such as quarantines, deletions, and alerts with no end-user disruption. The platform exposes cloud-hosted APIs and SDKs for developers to integrate data classification and protection capabilities into applications and data pipelines, helping organizations save time and keep business information safe.

Dgraph Labs is a software company that develops and operates a graph database designed for low-latency, real-time queries on large volumes of structured data. The database supports open-source use and enterprise deployments, including Slash Enterprise, a fully managed, serverless solution for workloads running on dedicated multi-zone clusters across AWS, Azure, or Google Cloud Platform. The platform enables efficient retrieval for real-time queries as well as semantic search, pattern matching, and fraud detection, helping organizations manage, represent, and visualize large datasets. Founded in 2016 and based in San Francisco, Dgraph Labs serves startups and larger enterprises seeking scalable graph data management.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Meltano is an open-source DataOps platform that integrates various leading open-source tools for managing the data lifecycle. It incorporates the Singer standard for data integration, featuring a library of over 200 connectors, as well as tools like dbt for data transformation, Airflow for orchestration, and plans to include Superset for data visualization. Meltano aims to simplify the processes of configuration, deployment, and monitoring while allowing data teams to adopt practices such as version control and continuous integration/continuous deployment. The platform collaborates with a community of over 1,200 professionals from startups, global enterprises, and consultancies to advance data infrastructure. Thousands of active projects utilizing Meltano are presently in operation across various organizations, demonstrating its practical application and adaptability in the data management landscape.

Moment is a provider of fixed‑income infrastructure and liquidity solutions for institutional and fintech clients. The company offers an institutional‑grade platform and APIs that power fixed‑income investing, combining trading, research, portfolio optimization, reporting, risk and compliance in a single system with automation. Moment serves global fintechs, traditional brokerages, and registered investment advisors, delivering modern fixed‑income tools to make markets more equitable and accessible. By unifying core fixed‑income functions and offering liquidity capabilities, Moment supports institutions in managing, pricing, and executing fixed‑income strategies at scale, enabling faster decision‑making and greater efficiency across the investment process.

Celcuity is a clinical-stage biotechnology company that discovers new cancer sub-types and therapeutic options using its proprietary CELsignia diagnostic platform. This platform analyzes living tumor cells to identify specific abnormal cellular processes driving cancer, enabling the development of targeted therapies for patients.

The Public Health Company is a pioneering firm that specializes in biosecurity solutions, offering a SaaS-enabled platform designed for the management of bio-risks. Founded in 2020 and headquartered in Palo Alto, California, the company leverages advanced technology and expert knowledge to address the challenges of enterprise risk management. Its platform focuses on identifying and mitigating physical world threats across various applications, providing clients with actionable and predictive intelligence. This enables organizations to implement dynamic risk management strategies efficiently and effectively, enhancing their preparedness against potential biohazards.

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms. Built by estate professionals and advisors, the platform allows advisors, planners, and estate attorneys to provide comprehensive and modern estate planning services to their clients. By streamlining the estate analysis process, Vanilla addresses inefficiencies in document preparation and improves both advisors' and clients' understanding of estate matters. The platform aims to simplify the complexities of estate management, thereby enabling advisors to strengthen client relationships, attract new business, and deliver ongoing value through effective estate planning solutions.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Quiq develops a cloud-based messaging platform that enables businesses to deliver personalized customer support across various channels at scale. Its AI-powered solutions facilitate seamless, proactive communication between brands and consumers via digital messaging channels.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Ocelot Bio is a biopharmaceutical company focused on developing therapies for severe liver disease, researching medicines to treat hepatorenal syndrome and advancing a therapeutic peptide that targets portal hypertension–related complications in end-stage liver disease to improve outcomes for patients with advanced liver disease.

Astronomer is a data engineering software company that builds a managed Apache Airflow platform. Founded in 2014 and based in Cincinnati, Astronomer offers Astro, a data orchestration platform powered by Apache Airflow that enables data teams to build, run, and observe data pipelines-as-code. The platform is designed to deploy, manage, and scale distributed Airflow workflows with features such as isolated resource allocation and controlled user access, supporting data engineers, data scientists, and data analysts in delivering trusted analytics. Astronomer's solutions help organizations increase data availability and visibility by making pipelines observable and governance-friendly across environments.

Founded in San Francisco in 2016, SmithRx specializes in designing and managing custom pharmacy benefit plans for companies. It leverages a modern technology platform to deliver flexibility, efficiency, and customer satisfaction, aligning incentives through data analytics.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Astrix Security specializes in safeguarding non-human identities, such as API keys, service accounts, and access tokens, by extending identity security to machines. Its cloud-based platform provides organizations with comprehensive visibility into these non-human identities, along with automated risk assessment and remediation capabilities. By managing the lifecycle of non-human identities, Astrix helps organizations mitigate excessive, unnecessary, and harmful access, thereby reducing the risk of service supply chain attacks and data breaches. The platform is designed to enable secure app-to-app integration and automation, allowing organizations to harness technology without compromising security.

Zero Networks Inc. is a network security software developer founded in 2019 and headquartered in Tel Aviv, Israel. The company specializes in automating the definition, enforcement, and adaptation of network access policies for users and machines within an organization. Its cloud-based technology customizes access controls by learning how users and devices communicate, thereby enhancing security without the need for agents or complex policy configurations. Additionally, Zero Networks incorporates a two-factor authentication mechanism that allows legitimate but unusual connections through a secure wall on mobile devices. This approach ensures robust protection against potential breaches while maintaining operational continuity, making it an effective solution for organizations seeking to strengthen their network security posture.

Decodable is a serverless data integration and engineering platform focused on streaming data, founded in 2021 by Eric Sammer and headquartered in San Francisco, California. The company offers a software solution that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates seamless connections to various existing messaging, storage, and database systems, allowing users to rapidly collect, process, and deliver data to both offline and online systems. Through its innovative approach, Decodable aims to simplify the management of streaming data, enhancing the capabilities of organizations in handling real-time data flows.

3Box Labs is a technology company based in New York that specializes in decentralized identity and data management solutions for web3 applications. Founded in 2018, it offers a suite of products including 3box.io, a social profiles application tailored for Ethereum users, and 3box.js, an API that facilitates user onboarding and data management for developers. Additionally, 3Box provides the 3box-dapp, which enables users to create and manage their social profiles, interact with decentralized applications, build reputations, and securely store data. The company's platform is designed to enhance user experience by ensuring that applications are lighter, more trustworthy, and carry reduced data management liabilities, thereby fostering a sustainable ecosystem where users have greater control over their data.

Running Tide optimizes aquaculture techniques to produce healthy, low-carbon protein while analyzing ocean data for carbon removal solutions.

Atom Computing Inc. is a technology company based in Berkeley, California, focused on the development of scalable quantum computers utilizing individual atoms. Founded in 2018, the company leverages the quantum mechanical properties of these atoms to process information and tackle complex problems that are beyond the capabilities of traditional computing. Atom Computing's innovative approach enables precise control, scaling, and stabilization of atoms, allowing quantum engineers and researchers to conduct advanced calculations in various fields, including drug design, computational chemistry, and other areas of general computing.

Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Suki develops AI-driven voice solutions for healthcare providers. Its primary product, Suki Assistant, uses artificial intelligence and natural language processing to create detailed clinical notes during or after consultations, enabling physicians to complete administrative tasks more efficiently.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.